Zacks Research Predicts Haemonetics’ Q4 Earnings (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Equities research analysts at Zacks Research raised their Q4 2026 earnings per share estimates for Haemonetics in a report released on Monday, December 9th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $1.40 per share for the quarter, up from their prior estimate of $1.39. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics’ FY2027 earnings at $5.92 EPS.

HAE has been the topic of a number of other research reports. Bank of America assumed coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective on the stock. Barrington Research reiterated an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research note on Wednesday, December 4th. JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Citigroup lowered their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Finally, CL King initiated coverage on Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $108.78.

Haemonetics Trading Down 1.2 %

Shares of NYSE:HAE opened at $82.30 on Thursday. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The stock has a market capitalization of $4.13 billion, a PE ratio of 34.17, a P/E/G ratio of 1.26 and a beta of 0.38. Haemonetics has a 1 year low of $70.25 and a 1 year high of $97.97. The firm has a fifty day moving average price of $80.91 and a 200 day moving average price of $81.63.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.99 earnings per share.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC grew its holdings in shares of Haemonetics by 3.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock worth $304,000 after purchasing an additional 117 shares during the last quarter. Vontobel Holding Ltd. increased its holdings in shares of Haemonetics by 3.8% in the third quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock worth $392,000 after acquiring an additional 180 shares in the last quarter. QRG Capital Management Inc. raised its position in shares of Haemonetics by 6.9% during the second quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier’s stock worth $333,000 after purchasing an additional 260 shares during the period. Arizona State Retirement System increased its stake in Haemonetics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock worth $1,176,000 after purchasing an additional 272 shares in the last quarter. Finally, Keene & Associates Inc. raised its holdings in Haemonetics by 3.0% during the 3rd quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier’s stock worth $818,000 after buying an additional 298 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.